Anika Therapeutics, Inc. (ANIK) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents mixed signals. The company shows strong product development and strategic initiatives, but financial guidance is weak with declining OEM revenue and negative EBITDA guidance. The Q&A reveals some positive developments, like the $40 million market opportunity and FDA encouragement, but also concerns about OEM dependency and lack of clarity on key metrics. Adjustments for new partnerships or financial metrics were not evident, leading to a neutral stock price reaction prediction.
Key Financial Performance
Revenue $28.2 million in total revenue for Q2 2025, an 8% decline compared to the same period in 2024. The decline was attributed to lower yields in manufacturing, a 10% decline in international OA pain sales, and a 13% decline in the OEM channel revenue.
Regenerative Solutions Revenue 41% year-over-year growth driven by the Integrity Implant System. Integrity has achieved sequential growth for 5 consecutive quarters and is on track to more than double in 2025 compared to 2024.
Gross Margin 51% for Q2 2025, down 16 percentage points from the same period last year. The decline was primarily due to a one-time $3 million charge related to lower production yields and a $3 million year-over-year decline in Monovisc and Orthovisc sales to J&J.
Operating Expenses $18.5 million in Q2 2025, down 17% year-over-year. The reduction was driven by a $3 million decrease in SG&A expenses and a 6% reduction in R&D expenses.
Adjusted EBITDA Negative $200,000 in Q2 2025, a decline of $4.9 million compared to the same period in 2024. The decrease was due to one-time scrap costs for manufacturing challenges and lower high-margin revenue from J&J.
Cash and Liquidity $53 million in cash and no debt at the end of Q2 2025. Operating cash flow improved to negative $200,000 compared to negative $1.1 million in the same period last year.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Hyalofast: The U.S. pivotal Phase III clinical trial for Hyalofast did not achieve statistical significance on its co-primary endpoints but showed consistent improvements over microfracture. Secondary endpoints achieved statistical significance, and the product has a strong international track record. The company plans to submit the final PMA module in the second half of 2025 and anticipates a commercial timeline extension to 2027.
Cingal: Progress was made toward NDA filing, with plans to initiate a bioequivalence study by year-end. This study addresses the final requirements before submission.
Integrity: The product exceeded its full-year 2024 performance and is on track to more than double in 2025. It led to 41% growth in Regenerative Solutions revenue this quarter. Two new Integrity shapes and sizes received 510(k) clearance and are planned for limited release by year-end.
Regenerative Solutions: Revenue grew by 41% year-over-year, driven by the Integrity Implant System. The shoulder remains the primary driver, but there is growing traction in other anatomies like the hip, knee, and ankle, representing a $40 million addressable market.
OEM Channel: Revenue declined by 13% due to lower pricing and demand for Monovisc and Orthovisc. However, Monovisc and Orthovisc continue to lead the U.S. market.
Manufacturing Challenges: Lower production yields for Monovisc and Cingal were resolved within the quarter, restoring output to historic levels. This issue caused a one-time $3 million charge and impacted gross margins.
Cost Management: Operating expenses were reduced by 17% year-over-year, driven by headcount-related cost savings and streamlined organizational structure.
Hyalofast Commercial Timeline: The commercial timeline for Hyalofast has been extended to 2027 to allow for thorough FDA review and dialogue.
Long-term Revenue Guidance: The commercial channel growth outlook for 2026 and 2027 has been revised to 10%-20% due to the extended FDA review process for Hyalofast.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Hyalofast Clinical Trial Results: The trial missed achieving statistical significance on its co-primary endpoints due to limitations in the study context, including a high dropout rate in the microfracture arm and missing data caused by COVID-related disruptions. This could delay FDA approval and extend the commercial timeline to 2027, impacting revenue projections.
Manufacturing Challenges: Lower production yields for Monovisc and Cingal in April and May led to a $3 million charge and reduced shipments, slightly impacting commercial revenue. Although resolved, this issue highlights operational vulnerabilities.
OEM Channel Revenue Decline: Revenue in the OEM channel declined 13% due to pricing pressures and demand challenges for Monovisc and Orthovisc. This continues to be a headwind for the company’s financial performance.
Regulatory and Approval Risks: The Hyalofast trial results and the extended timeline for FDA review could delay market entry and revenue generation. Additionally, the Cingal bioequivalence study and toxicity studies are still pending, adding uncertainty to the approval process.
Revenue Pressure from J&J Partnership: Lower pricing and demand for Monovisc and Orthovisc, which are controlled by J&J, are impacting revenue. The company has limited control over pricing and sales in this channel.
Economic and Market Risks: The company faces pricing declines and competitive pressures in its key markets, particularly in the U.S. OA Pain market.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Hyalofast FDA Submission and Commercial Timeline: Anika plans to submit the third and final PMA module for Hyalofast in the second half of 2025. The company anticipates extending the commercial timeline to 2027 to allow for thorough FDA review and dialogue. Full market release is expected in 2028, with a $3 million revenue contribution projected for 2027.
Cingal NDA Filing: The company is on track to initiate the bioequivalence study for Cingal by year-end 2025. This study, along with earlier toxicity studies, addresses the final requirements before submission. An update on the program timing will be provided after the study begins.
Integrity Implant System Growth: Integrity is expected to more than double its revenue in 2025 compared to 2024. The product has achieved sequential growth for five consecutive quarters and is expanding its application across various tendon repair procedures. Two new Integrity shapes and sizes are planned for limited release by year-end 2025, with modest revenue contributions expected initially but positive impacts on future sales.
Commercial Channel Revenue Guidance: The commercial channel is expected to generate $47 million to $49.5 million in revenue for 2025, representing 12% to 18% growth. Long-term growth projections for the commercial channel have been revised to 10% to 20% for 2026 and 2027, reflecting a possible extension of the FDA review process for Hyalofast.
OEM Channel Revenue Guidance: The OEM channel is projected to deliver $62 million to $65 million in revenue for 2025, reflecting a 16% to 20% decline compared to 2024. This decline is attributed to lower pricing for Monovisc and Orthovisc, despite higher volumes.
Adjusted EBITDA Guidance: The adjusted EBITDA guidance range for 2025 is maintained at negative 3% to positive 3%. This reflects impacts from lower manufacturing yields, reduced pricing for Monovisc and Orthovisc, and costs associated with the Cingal bioequivalence study.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What will drive the sequential improvement in gross margins to 62%-63% in the back half of the year?
A:The improvement is driven by the fact that many of the charges from the beginning of the quarter are one-time in nature. Excluding these, the business performed well. Gross margins for Q2, excluding the one-time impact, were above 60%, and the second half will be slightly below that. The pricing dynamic for J&J on Monovisc and Orthovisc is also a factor.
Q:Do you have any progress to report on additional OEM partnerships to diversify your OEM revenue away from J&J?
A:There is no progress to report currently. The company continues to assess opportunities, and Cingal is expected to fit into the OEM channel. Progress on this will become more visible as they move closer to an NDA filing.
Q:How should we think about the expanded market opportunity with the new configurations for foot, ankle, knee, and hip for Integrity?
A:The new shapes and sizes of Integrity are expected to address an additional $40 million market opportunity. These configurations are more purpose-fit and designed for specific anatomical locations, which will increase opportunities going forward. This year is focused on a limited release and preparation, with a more material impact expected next year.
Q:What gives you confidence that the FDA could approve Hyalofast based on secondary endpoints and international data despite missing primary endpoints?
A:Hyalofast falls under the breakthrough device designation, and the FDA has encouraged the company to submit all data, including secondary endpoints. The study was impacted by missing data due to changes in medical practice and COVID-related issues. The secondary endpoints achieved statistical significance and are consistent with data used for other approved products. The company also has a robust data package from over 15 years of clinical experience internationally.
Q:How should we think about gross margin going forward as the commercial channel becomes a bigger piece of the revenue?
A:The commercial channel currently has a lower gross margin due to international products being sold at lower price points. However, growth in higher-margin new products like Integrity and Hyalofast is expected to offset this. Gross margins are expected to remain in the range shared for the second half of the year.
Q:Could you sign a distribution deal for Cingal prior to FDA approval?
A:The decision on timing for a distribution deal will be driven by the best way to maximize shareholder value. Progress is being made with the FDA, and updates on the timeline will be provided once the bioequivalent study begins.
Q:Can we assume cash on hand will start to increase going forward?
A:The company expects improvements in operating cash flow. However, cash balance may be impacted by strategic CapEx investments, particularly in the Massachusetts facility. These investments are necessary to meet demand for products like Integrity, Cingal, and Hyalofast.
Q:Will the company have sufficient capacity to meet demand for Integrity, Cingal, and Hyalofast by the end of the year?
A:The company is making continued investments in its facility. The current level of CapEx is expected to meet the ramp for next year, but further upgrades will be needed, especially for Cingal and cross-link products.
Q:How many patients did you have full data on in the Hyalofast trial?
A:The company has not reported the details of the full data set yet as analysis is ongoing. The study design targeted 200 patients, but there were dropouts, particularly in the microfracture arm, due to changes in clinical practice and COVID-related issues. Full data analysis will be disclosed once completed.
Q:Is it typical for the FDA to encourage submission of a full data package despite missing primary endpoints?
A:The FDA has encouraged the company to submit the full data package, including secondary endpoints and international data. This is not necessarily standard but reflects the breakthrough device designation and the FDA's understanding of the missing data issues.
Q:Is the $14 million investment in the regenerative portfolio still on track?
A:Yes, the $14 million investment is still on track. The company is consistently evaluating strategic investments to optimize shareholder value, and adjustments may be made in the future.
Q:Do you have any updates on surgeon adoption or surgery numbers for Integrity?
A:No specific updates on surgery numbers were provided. However, the company is on track to double the business this year, indicating strong adoption and performance.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer or lacked clarity on the following: 1. Progress on additional OEM partnerships to diversify revenue away from J&J. 2. Specific details on the number of patients with full data in the Hyalofast trial. 3. Whether the $14 million investment in the regenerative portfolio might be curbed in the second half of the year. 4. Updates on surgeon adoption or surgery numbers for Integrity.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
FDA approval
Function
Hall Director
Hyalofast improvement
Hyalofast trial
Inc Research
KOOS
Research Division
ability
analysis
application
arm
cartilage lesion
charge
combination
comparator
country
decline period
demand
driver
endpoint significance
impact
improvement microfracture
level
line expectation
manufacturing challenge
microfracture study
momentum
order
production
scrap
shipment
significance endpoint
standard care
study significance
tendon
totality
treatment
yield
ANIK Transcript
Anika Therapeutics, Inc. (ANIK) Q1 2026 Earnings Call Transcript
Positive4-29
The earnings call reveals strong revenue growth, improved gross margins, and a completed $15 million stock repurchase plan, signaling financial health and shareholder value. Despite uncertainties in FDA timelines and lack of clarity in some responses, the company's strategic focus on international markets and surgeon training suggests robust market expansion potential. The positive financial metrics and optimistic guidance outweigh the concerns, leading to a positive stock price prediction.
Anika Therapeutics, Inc. (ANIK) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call presents mixed signals: strong growth in international OA pain management and commercial channels, but a decline in OEM revenue and gross margin. Positive aspects include a strong adjusted EBITDA and operational improvements, but uncertainties in guidance and management's lack of specificity in the Q&A may dampen sentiment. Given the mixed financial outlook and market dynamics, the stock price is likely to remain stable, resulting in a neutral prediction.
Anika Therapeutics, Inc. (ANIK) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call presents mixed signals. The company's revenue and gross margin decline, OEM channel issues, and increased R&D costs are concerning. However, the commercial channel's growth, share repurchase program, and resolved production issues provide positive aspects. The Q&A session highlighted optimism in product development but lacked clear timelines for key projects. Given these mixed factors and the absence of strong catalysts, the stock price is likely to remain stable in the short term, resulting in a neutral rating.
Anika Therapeutics, Inc. (ANIK) Q2 2025 Earnings Call Transcript
Unknown7-30
The earnings call summary presents mixed signals. The company shows strong product development and strategic initiatives, but financial guidance is weak with declining OEM revenue and negative EBITDA guidance. The Q&A reveals some positive developments, like the $40 million market opportunity and FDA encouragement, but also concerns about OEM dependency and lack of clarity on key metrics. Adjustments for new partnerships or financial metrics were not evident, leading to a neutral stock price reaction prediction.
ANIK Slides
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
